<?xml version="1.0" encoding="iso-8859-1" standalone="no" ?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader lang="en">
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>2.0</messageformatrelease>
    <messagenumb>PRO000000000000509990</messagenumb>
    <messagesenderidentifier>EMDSERONO</messagesenderidentifier>
    <messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20130125161150</messagedate>
  </ichicsrmessageheader>
  <safetyreport lang="en">
    <safetyreportversion lang="en">0</safetyreportversion>
    <safetyreportid lang="en">CA-US-EMD Serono, Inc.-7188377</safetyreportid>
    <primarysourcecountry>CA</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20130125</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20130116</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20130116</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb lang="en">CA-Merck KGaA-7188377</companynumb>
    <medicallyconfirm>1</medicallyconfirm>
    <primarysource>
      <reporterfamilyname>Unknown</reporterfamilyname>
      <reportercountry>CA</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <senderorganization>US-EMD Serono, Inc.</senderorganization>
      <senderdepartment>US Product Surveillance and Quality Assurance</senderdepartment>
      <sendertitle>Dr</sendertitle>
      <sendergivename>Daryl</sendergivename>
      <senderfamilyname>Dawson</senderfamilyname>
      <senderstreetaddress>One Technology Place</senderstreetaddress>
      <sendercity>Rockland</sendercity>
      <senderstate>MA</senderstate>
      <senderpostcode>02370</senderpostcode>
      <sendercountrycode>US</sendercountrycode>
      <sendertel>781-681</sendertel>
      <sendertelextension>2564</sendertelextension>
      <sendertelcountrycode>+1</sendertelcountrycode>
      <senderfax>781-681</senderfax>
      <senderfaxextension>2961</senderfaxextension>
      <senderfaxcountrycode>+1</senderfaxcountrycode>
      <senderemailaddress>usps@emdserono.com</senderemailaddress>
    </sender>
    <receiver>
      <receivertype>2</receivertype>
      <receiverorganization>US-A-Food and Drug Administration</receiverorganization>
      <receiverdepartment>AERS</receiverdepartment>
      <receivertitle>Mr</receivertitle>
      <receivergivename>Roger</receivergivename>
      <receivermiddlename>CDER</receivermiddlename>
      <receiverfamilyname>Goetsch</receiverfamilyname>
      <receiverstreetaddress>12300 TwinbrookParkway, Suite 240</receiverstreetaddress>
      <receivercity>Rockville</receivercity>
      <receiverstate>MD</receiverstate>
      <receiverpostcode>20851</receiverpostcode>
      <receivercountrycode>US</receivercountrycode>
      <receivertel>3017709299</receivertel>
      <receivertelcountrycode>001</receivertelcountrycode>
      <receiverfax>3017706614</receiverfax>
      <receiverfaxcountrycode>001</receiverfaxcountrycode>
      <receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
    </receiver>
    <patient lang="en">
      <patientonsetage>47</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>2</patientsex>
      <reaction>
        <primarysourcereaction lang="en">EPISTAXIS</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10015090</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10015090</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">MENORRHAGIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10027313</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10027313</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE HAEMORRHAGE</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022067</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022067</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">THROMBOCYTOPENIA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10043554</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10043554</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <primarysourcereaction lang="en">INJECTION SITE HAEMATOMA</primarysourcereaction>
        <reactionmeddraversionllt>15.1</reactionmeddraversionllt>
        <reactionmeddrallt>10022066</reactionmeddrallt>
        <reactionmeddraversionpt>15.1</reactionmeddraversionpt>
        <reactionmeddrapt>10022066</reactionmeddrapt>
        <termhighlighted>4</termhighlighted>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REBIF</medicinalproduct>
        <drugauthorizationnumb>103780</drugauthorizationnumb>
        <drugauthorizationcountry>US</drugauthorizationcountry>
        <drugstructuredosagenumb>44</drugstructuredosagenumb>
        <drugstructuredosageunit>004</drugstructuredosageunit>
        <drugseparatedosagenumb>3</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosageform lang="en">Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <actiondrug>5</actiondrug>
        <activesubstance>
          <activesubstancename>INTERFERON BETA-1A</activesubstancename>
        </activesubstance>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10015090</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10015090</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10027313</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10027313</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022067</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022067</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043554</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10043554</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022066</drugreactionasses>
          <drugassessmentsource lang="en">Reporter</drugassessmentsource>
          <drugresult lang="en">Not reported</drugresult>
        </drugreactionrelatedness>
        <drugreactionrelatedness lang="en">
          <drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
          <drugreactionasses>10022066</drugreactionasses>
          <drugassessmentsource lang="en">Company</drugassessmentsource>
          <drugresult lang="en">Suspected</drugresult>
        </drugreactionrelatedness>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Elavil</medicinalproduct>
        <drugstructuredosagenumb>5</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>2</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosageform lang="en">Tablet</drugdosageform>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <drugtreatmentduration>1</drugtreatmentduration>
        <drugtreatmentdurationunit>801</drugtreatmentdurationunit>
      </drug>
      <drug>
        <drugcharacterization>2</drugcharacterization>
        <medicinalproduct>Tegretol</medicinalproduct>
        <drugstructuredosagenumb>100</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugindicationmeddraversion>15.1</drugindicationmeddraversion>
        <drugindication>10070592</drugindication>
        <drugtreatmentduration>3</drugtreatmentduration>
        <drugtreatmentdurationunit>801</drugtreatmentdurationunit>
      </drug>
      <summary lang="en">
        <narrativeincludeclinical lang="en">This spontaneous case report from an other healthcare professional in Canada was received via the Canadian Health Authority (Health Canada) (000143822) at Merck Serono on 16 Jan 2013.
A 47-year-old female patient experienced epistaxis, menorrhagia, injection site haemorrhage, thrombocytopenia and injection site haematoma  while being treated with Rebif.
The events epistaxis, menorrhagia, injection site haemorrhage, thrombocytopenia and injection site haematoma were assessed as medically significant by the reporter. 
No relevant medical history was reported.
The patient's concomitant medications included Elavil (amitriptyline) tablet at a dose of 5.0 mg two times a day from an unspecified date for an unknown indication and Tegretol (carbamazepine) at a dose of 100 mg as required from an unspecified date for an unknown indication.
The patient received Rebif (interferon beta 1a) at a dose of 44 mcg three times a week subcutaneously from an unspecified date for an unknown indication.
On an unspecified date, the patient had epistaxis, menorrhagia, injection site haemorrhage, thrombocytopenia and injection site haematoma.
At the time of reporting, action taken with Rebif was not reported.
At the time of reporting, the events were not recovered.
The reporter did not provide any causality assessment.</narrativeincludeclinical>
        <sendercomment lang="en">Epistaxis [Epistaxis], menorrhagia [Menorrhagia], injection site haemorrhage [Injection site haemorrhage], thrombocytopenia [Thrombocytopenia] and injection site haematoma [Injection site haematoma] in a 47-year-old female patient while being treated with Rebif. 
Temporal relationship: compatible. Latency: Not assessable (therapy start date and events onset dates not reported). Dechallenge: not applicable (action taken with Rebif therapy not reported).
Alternative explanation: Epistaxis, menorrhagia, injection site haematoma and haemorrhage could be related to the concurrent thrombocytopenia. Concomitant treatment with carbamazepine and amitriptyline could have contributed to the occurrence of this thrombocytopenia.
Evaluation by reporter (healthcare professional): not reported.
Evaluation by company: In absence of sufficient information to fully assess the case, epistaxis, menorrhagia and injection site haemorrhage have been assessed as causally related to Rebif. Thrombocytopenia and injection site haematoma are assessed as related to Rebif.
Epistaxis, Menorrhagia and Injection site haemorrhage are unlisted and Thrombocytopenia and Injection site haematoma are listed for Rebif as per reference safety information. 

Follow-up information has been requested: causality assessment, Rebif therapy details (therapy dates, indication, action taken), events onset dates and values of thrombocytes (severity of thrombocytopenia).</sendercomment>
      </summary>
    </patient>
  </safetyreport>
</ichicsr>
